Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma

被引：26

作者：

Dobrzycka, Bozena ^{[1
]}

Terlikowski, Slawomir J. ^{[1
]}

Mazurek, Andrzej ^{[2
]}

Kowalczuk, Oksana ^{[3
]}

Niklinska, Wieslawa ^{[4
]}

Chyczewski, Lech ^{[3
]}

Kulikowski, Marek ^{[1
]}

机构：

[1] Med Univ Bialystok, Dept Gynecol & Obstet Nursing, PL-15062 Bialystok, Poland

[2] Med Univ Bialystok, Dept Gynecol, PL-15062 Bialystok, Poland

[3] Med Univ Bialystok, Dept Clin Mol Biol, PL-15062 Bialystok, Poland

[4] Med Univ Bialystok, Dept Histol & Embryol, PL-15062 Bialystok, Poland

来源：

FOLIA HISTOCHEMICA ET CYTOBIOLOGICA | 2009年 / 47卷 / 01期

关键词：

endometrial carcinoma; endometrial hyperplasia; KRAS; point mutation; molecular detection; POINT MUTATIONS; RAS ONCOGENE; CANCER; PATIENT; TUMORS;

D O I：

10.2478/v10042-009-0014-2

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The aim of this study was to examine the prevalence and clinicopathological significance of KRAS point mutation in endometrial hyperplasia and carcinoma. We analysed KRAS in 11 cases of complex atypical hyperplasia and in 49 endometrial carcinomas using polymerase chain reaction associated with restriction fragment length polymorphism (PCR-RFPL). Point mutations at codon 12 of KRAS oncogene were identified in 7 of 49 (14.3%) tumor specimens and in 2 of 11 (18.2%) hyperplasias. No correlation was found between KRAS gene mutation and age at onset, histology, grade of differentiation and clinical stage. We conclude that KRAS mutation is a relatively common event in endometrial carcinogenesis, but with no prognostic value.

引用

页码：65 / 68

页数：4

共 20 条

[1]

Abal M, 2006, HISTOL HISTOPATHOL, V21, P197, DOI 10.14670/HH-21.197

[2] Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis [J].